+65 3158 9940
1300 798 820
+64 9801 0299
Singapore, 06 November 2020: A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be available to patients in Australia, New Zealand and in some parts of South East Asia, following an exclusive distribution agreement. Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an agreement with US-based Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to commercialise the
Melbourne, Australia, 8 October 2020: Independent pharmaceutical company Specialised Therapeutics Australia (STA) has been recognised as an Employer of Choice in The Australian Business Awards 2020. The prestigious awards recognize organisations demonstrating business innovation, product innovation, technological achievement and employee engagement via a set of comprehensive award categories. The Employer of Choice (EOC) accolade in particular,
We are so proud, that in an exceptional field of finalists (including some or the world’s biggest pharma companies) it was our breast cancer patient support program that took out top prize. Special thanks to our program collaborators Pharmacy Phusion for their support and assistance overseeing this tremendous effort.
Singapore and Melbourne, Australia, 14 October 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients in Australia, New Zealand and throughout SE Asia. Under the terms of the agreement, STA will provide the marine-derived compound YONDELIS (trabectedin) to patients
Singapore, September 1, 2018: A DRUG currently used to treat Chronic Myeloid Leukaemia (CML) will be available on the Pharmaceutical Benefits Scheme from today as a new treatment for another aggressive form of the disease. The drug, ICLUSIG (ponatinib) will now be available to all Philadelphia-positive Acute Lymphoblastic Leukaemia (Ph+ ALL) patients, who are intolerant
Singapore, 23 November 2017: A NEW breast cancer drug shown to reduce the risk of cancer recurrence will soon be made available in Australia, New Zealand and throughout South-East Asia, following a key license deal between Specialised Therapeutics Asia (ST Asia) and US biopharmaceutical company Puma Biotechnology, Inc. (NASDAQ: PBYI). Under the terms of the
SINGAPORE and MELBOURNE, Australia, May 17, 2017: International biopharmaceutical company Specialised Therapeutics Asia (ST Asia) is set to commercialise a promising new anti-cancer drug throughout South East Asia, after signing a second major licensing deal with European pharmaceutical company PharmaMar. The latest agreement allows ST Asia marketing and distribution rights to new anti-cancer compound lurbinectedin
SARAH-JANE TASKER | THE AUSTRALIAN| MARCH 19, 2016 12:00AM From Big Pharma to Small Starts: Risking it All on a Life-Saving Cancer Drug to Win Bozena Zembrzuski and Carlo Montagner reflect on their decision to found Specialised Therapeutics and bring Abraxane to Australia. Picture: Aaron Francis After years working for big pharma in the US,
SINGAPORE and MELBOURNE, Australia, Feb. 2, 2016 /PRNewswire/ — International biopharmaceutical company Specialised Therapeutics Asia (ST Asia) will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar. Under the terms of the latest agreement, ST Asia will be allowed marketing and distribution rights
Melbourne, Australia, and Lugano, Switzerland, 8 May 2015: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration (TGA) has approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.